Table S1 List of short hairpin RNA sequences against ARHGAP25 and primer sequences for cloning the coding region of ARHGAP25.

pLKO.1 shARHGAP25-1	Forward	CCGGTCCATCCTTCCTCGTGACAACTCGAGTT GTCACGAGGAAGGATGGTTTTTG
	Reverse	AATTCAAAAACCATCCTTCCTCGTGACAACTC GAGTTGTCACGAGGAAGGATGGA
pLKO.1 shARHGAP25-2	Forward	CCGGTGGACTCAAACACTCCCTAACTCGAGTT AGGGAGTGTTTGAGTCCTTTTTG
	Reverse	AATTCAAAAAGGACTCAAACACTCCCTAACTC GAGTTAGGGAGTGTTTGAGTCCA
Primers for cloning	Forward	5’ -CGGAATTCATGTCCCTAAAATTGCCAAGG-3’
	Reverse	5’-CGGGATCCTTAAGCCTCGGTCTTG-3’

Figure S1. Mice were inoculated subcutaneously with AsPC-1 cells stably transfected with vector control or OE-ARHGAP25 (n=6 in each group).

Figure S2. Mice were inoculated subcutaneously with BxPC-3 cells stably transfected with vector control or sh-ARHGAP25 (n=6 in each group).

sh-NC

sh-ARHGAP25-1

sh-ARHGAP25-2

Figure S3. Representative images (left panel) and quantification (right panel) of immunofluorescence staining with Ki-67 in xenograft tumors stably transfected as indicated were shown, Scale bar: 50 μm. Data are shown as the mean ± SD (n ≥ 3). $^{**}P < .01$, $^{***}P < .001$.



Figure S4. Both AsPC-1 and BxPC-3 cells were treated with a serial concentration of gemcitabine or 5-fluorouracil for 72 h. The relative cell viability was evaluated using the CCK-8 assay. The IC50 values of gemcitabine or 5-fluorouacil were also shown.



Cell line	AsPC-1	BxPC-3
IC50 GEM (μM)	0.504	3.048



Cell line	AsPC-1	BxPC-3
IC50 5-FU (μM)	5.778	7.846